The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer tried to end the losing streak by moving its PDE4B inhibitor nerandomilast into a phase 3 program in 2022.
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
GlobalData on MSN5d
Boehringer seeks approval for lung fibrosis drug following Phase III winThe Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
Boehringer Ingelheim said that it will submit a new drug application for nerandomilast based on the positive results.
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...
Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive ...
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback